Wall Street Zen downgraded shares of Nektar Therapeutics (NASDAQ:NKTR – Free Report) from a hold rating to a sell rating in a report released on Saturday,Wall Street Zen reports.
Several other equities research analysts have also recently issued reports on NKTR. BTIG Research restated a “buy” rating and set a $178.00 price objective on shares of Nektar Therapeutics in a research report on Friday, October 9th. UBS Group started coverage on shares of Nektar Therapeutics in a research note on Monday, October 12th. They set a “neutral” rating and a $53.00 target price on the stock. Wedbush decreased their target price on shares of Nektar Therapeutics from $80.00 to $50.00 and set a “neutral” rating on the stock in a report on Wednesday, September 23rd. Weiss Ratings reissued a “sell (d-)” rating on shares of Nektar Therapeutics in a research note on Friday, August 28th. Finally, Leerink Partners started coverage on shares of Nektar Therapeutics in a research note on Monday, October 12th. They issued an “outperform” rating and a $130.00 price target for the company. One investment analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $130.33.
Check Out Our Latest Analysis on NKTR
Nektar Therapeutics Stock Down 2.2%
Shares of NASDAQ:NKTR opened at $36.44 on Friday. The business has a fifty day moving average of $47.72 and a two-hundred day moving average of $64.54. The stock has a market cap of $1.24 billion, a P/E ratio of -5.64 and a beta of 1.44. Nektar Therapeutics has a 52-week low of $33.40 and a 52-week high of $109.00.
Nektar Therapeutics (NASDAQ:NKTR – Get Free Report) last issued its earnings results on Thursday, November 12th. The biopharmaceutical company reported ($1.63) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.07) by $0.44. Nektar Therapeutics had a negative return on equity of 33.89% and a negative net margin of 339.67%. The business had revenue of $9.39 million during the quarter, compared to the consensus estimate of $10.27 million. On average, equities analysts anticipate that Nektar Therapeutics will post -8.08 earnings per share for the current year.
Institutional Trading of Nektar Therapeutics
A number of hedge funds and other institutional investors have recently modified their holdings of NKTR. Two Seas Capital LP raised its holdings in Nektar Therapeutics by 8.2% in the 3rd quarter. Two Seas Capital LP now owns 3,345,978 shares of the biopharmaceutical company’s stock valued at $202,582,000 after buying an additional 253,744 shares during the period. Goldman Sachs Group Inc. boosted its stake in Nektar Therapeutics by 171.9% during the third quarter. Goldman Sachs Group Inc. now owns 621,249 shares of the biopharmaceutical company’s stock worth $37,614,000 after buying an additional 392,759 shares during the period. Braidwell LP boosted its stake in Nektar Therapeutics by 112.7% during the second quarter. Braidwell LP now owns 473,617 shares of the biopharmaceutical company’s stock worth $33,063,000 after buying an additional 250,916 shares during the period. Orbimed Advisors LLC purchased a new position in Nektar Therapeutics during the first quarter worth about $19,786,000. Finally, ADAR1 Capital Management LLC increased its position in shares of Nektar Therapeutics by 123.9% during the first quarter. ADAR1 Capital Management LLC now owns 161,252 shares of the biopharmaceutical company’s stock valued at $11,602,000 after acquiring an additional 89,221 shares during the last quarter. 75.88% of the stock is owned by institutional investors and hedge funds.
About Nektar Therapeutics
Nektar Therapeutics is a clinical-stage biopharmaceutical company based in San Francisco, California. It discovers and develops medicines, with a current focus on treatments for autoimmune and inflammatory diseases. Its lead investigational program, rezpegaldesleukin (REZPEG), is designed to stimulate regulatory T cells, which help regulate immune responses. Nektar is studying the candidate in clinical trials for immune-mediated conditions; it is not an approved medicine. Founded in 1990 as Inhale Therapeutic Systems, the company later adopted the Nektar name as it expanded its drug-development work.
Read More
- Five stocks we like better than Nektar Therapeutics
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
